In recent years, the role of immune cells in tumor progression has been a matter of increasing interest. Neutrophils constitute an important portion of the immune cells infiltrating the tumor microenvironment. Traditionally viewed as the first line of defense against infections, it is now well accepted that neutrophils also have an important role in multiple aspects of cancer biology. Multiple and heterogeneous neutrophil subsets have been identified in tumors and in circulation. Evidence from many studies now supports the notion that tumor-associated neutrophils (TANs) show functional plasticity driven by multiple factors present in the tumor microenvironment. In this review, we first concisely discuss the pro-tumor vs. anti-tumor nature of neutrophils in cancer, their functional plasticity, and the mechanisms that regulate neutrophil polarization. We then expand on the various crosstalks and mutual effects between TANs and other tumor-infiltrating immune cell types, emphasizing the active role of neutrophils as regulators of the immune system, promoting or inhibiting the establishment of a permissive tumor microenvironment. Finally, the possible modulation of cancer-related neutrophils by therapies directed toward immune checkpoints is discussed briefly.
Introduction
The contribution of nonmalignant cells present in the tumor microenvironment to tumor growth is now indisputable [1, 2] . Multiple immune cell types, including neutrophils, macrophages, DCs, NK cells, T cells, and B cells, have been shown to infiltrate the tumor and participate in the modulation of the tumor microenvironment together with other nonimmune stromal cells (e.g., fibroblast and endothelial cells). In the context of cancer, the immune system, which primarily acts to protect the host against a wide variety of infections and threats, undergoes a dramatic modulation which is regarded as "alternative activation" [3, 4] . This switch to an alternative state of activation can be associated with the "angiogenic switch," which modulates the endothelial cells lining the intratumoral blood vessels and is crucial for further tumor development. We have, therefore, recently referred to this process as an "immunosuppressive switch"; during which, the polarization of the tumor-infiltrating immune cells is modulated to support tumor growth and progression [5] . Multiple mechanisms promoting such a switch were found by us and by others to involve major immune cell types infiltrating the tumor and to occur along with tumor progression [6] [7] [8] .
Neutrophils make up a significant portion of the inflammatory cell infiltrate in many types of cancer [9] [10] [11] [12] , but the mechanisms by which TANs affect tumor progression are only now being investigated. Multiple studies have pointed toward the tumorpromoting effects of neutrophils. Histologic studies performed on a variety of tumor types have shown that high levels of intratumoral neutrophils are associated with poor outcomes in patients with cancer [13] . In addition, tumor-infiltrating neutrophils have been suggested to promote metastatic seeding to distant organs [14, 15] and to support angiogenesis [16, 17] . In contrast, other studies have provided evidence for the antitumoral effects of neutrophils, showing that neutrophils are capable of direct cytotoxicity toward tumor cells [18] and can attenuate the formation of metastases [19, 20] . The supportive vs. antitumor roles of neutrophils in cancer have been a subject of debate, but the growing data from both animal models and human studies demonstrate that TANs have an important role in several aspects of tumor development, from malignant transformation to tumor progression, modification of the ECM, angiogenesis, cell migration, and immunosuppression [21] [22] [23] [24] . In addition to the phenotypic modulation of neutrophils by tumor cells themselves, the implications of possible interactions between neutrophils and other types of tumor-infiltrating immune cells have recently been the subject of growing interest.
In this review, we will explore TANs' phenotypic modulation with tumor progression, describe known crosstalks among neutrophils and other tumor-infiltrating immune cells, and assess the impact of TANs on tumor progression.
THE FUNCTIONAL PLASTICITY OF TANS ALONG WITH TUMOR PROGRESSION
Findings describing a phenotypic modulation of tumorinfiltrating neutrophils by cues present in the tumor microenvironment have led to the notion that the functional plasticity seen in other immune cells, such as TAMs, [25] applies to TANs as well. Cytokine-driven polarization of neutrophils in murine models of cancer has been exemplified in recent years by us and by others, showing that TANs can be modulated toward a protumorigenic (N2) phenotype by the presence of TGF-b [26] , or by an antitumor (N1) phenotype through blocking TGF-b or type-I IFNs [27, 28] . TGF-b was shown to prevent the production of ROS, reactive nitrogen intermediates, and IL-1b by tumor neutrophils and to inhibit neutrophil degranulation in response to LPS. In contrast, inhibition of TGF-b signaling was shown to confer antitumorigenic activity to neutrophils, which was associated with an alteration in chemokine and cytokine profile, higher infiltration of neutrophils in tumors, and increased ICAM1 expression on endothelial cells [26, 28] .
IFN-b-deficient mice present increased tumor growth, angiogenesis, and metastasis associated with skewed N2 phenotype neutrophils. Neutrophil depletion in this model reversed the observed phenotype. In contrast, in the presence of type-I IFNs, TANs display an antitumor N1 phenotype with increased tumor cytotoxicity, high NET expression, high ICAM1 and TNF-a expression [27] . Additional cytokines, such as G-CSF, IFN-g, TNF-a, and IL-8, have been shown to promote changes in neutrophil characteristics and functions or the specific recruitment of neutrophil subpopulations [19, 20, [29] [30] [31] .
The finding that TANs isolated from early tumors in mice show higher cytotoxicity toward tumor cells than those from established tumors (greater secretions of TNF-a, NO, and H 2 O 2 ) [32] led to the hypothesis of an N1-to-N2 modification during tumor progression. In addition to a change in activation state, we showed that TANs at early stages of tumor development are localized almost exclusively at the periphery of the tumor, whereas, at later stages, TANs are found scattered among the tumor cells. Importantly, this hypothesis of an N1/N2 dichotomy of neutrophils has not been clearly demonstrated in humans yet.
Neutrophils, like all other leukocytes, migrate from the blood into tissues under the influence of specific chemokines (e.g., KC/CXCL-1 and MIP2a/CXCL2 in mice) and cytokines (e.g., IL-8, TNF-a, IFN-g) [31] . The possibility of an autocrine mechanism, by which TANs at least partly mediate further neutrophil infiltration into the tumor, has been suggested [33, 34] . In accordance with that view, we indeed found in mice that the expression of known neutrophil chemoattractants, such as Cxcl1, Cxcl2 and Ccl2, was strongly up-regulated in TAN compared with bone marrow neutrophils [35] . It seems, therefore, that the neutrophils could initiate a positive feedback loop to promote the recruitment of more neutrophils into the tumor. Therefore, during tumor development, the tumor microenvironment modulates the chemotactic forces and infiltration of neutrophils.
In addition to the identification of tumor-infiltrating neutrophil subtypes, distinct subpopulations of circulating neutrophils have recently been described both in mice and in patients with advanced cancer [36] . At least 3 distinct neutrophil populations are found in the circulation during cancer progression. These may be roughly divided into mature high-density neutrophils, mature LDNs, and immature LDNs. Although the mature highdensity neutrophil subtype was shown to present an N1-like phenotype and to have the capacity to kill tumor cells, mature LDNs are not cytotoxic but display impaired functionality and suppressive properties [36] . Interestingly, the circulating LDN subpopulation include significant numbers of true granulocytic MDSCs, which currently, can be distinguished only by their immature morphology [36] .
The emergence of MDSCs, initially defined in mice as CD11b/ GR1 double-positive cells, adds an additional complexity to the understanding of the different cancer-driven myeloid subpopulations [37, 38] . MDSCs are immature myeloid cells that do not terminally differentiate into granulocytes, macrophages, or DCs and exhibit immunosuppressive functions by multiple mechanisms. Unfortunately, no clear membrane marker currently exists to differentiate between neutrophils and granulocytic MDSCs in the circulation of tumor-bearing mice or patients with cancer. The GR1 marker includes both the granulocytic Ly6G and the monocytic Ly6C Ags [39, 40] ; therefore, discrimination and classification of granulocytic MDSCs vs. TANs remains a subject of debate.
MDSCs are significantly increased in the tumor, spleen, and blood of tumor-bearing mice and are suggested to accumulate in the circulation with tumor progression until they eventually enter the tumor site itself. A long list of factors secreted at the tumor site modulates MDSC production, recruitment, and activation, including growth factors (M-CSF, G-CSF, vascular endothelial growth factor, TGF-b), cytokines (TNF-a, IFN-g, IL-1b, IL-4, IL-5, IL-6, IL-10, IL-13), and chemokines (CCL2, CCL4, CCL5, CXCL1, CXCL8, CXCL12) [41] . Major immunosuppressive activities of MDSCs have been linked to the expression of Arg1 and Nos2, which were shown, for instance, to inhibit cytokine production required for T cell antitumor activity and to mediate T cell suppression [42] .
NEUTROPHILS AS AN ACTIVE, INTRATUMORAL SOURCE OF CYTOKINES AND CHEMOKINES
Neutrophils recruited to the tumor site actively secrete cytokines and chemokines, which can enhance not only their own recruitment but also the recruitment, activation, and polarization of other tumor-supportive immune cells in the tumor microenvironment, thereby, affecting the possibility of the immune system to influence tumor growth [22] . Using transcriptomic analysis, we have shown that TANs in mice display a dramatically different transcriptomic profile than both granulocytic MDSCs and naive bone marrow neutrophils, with prominent differences in the expression of a wide range of cytokines and chemokines [35] . In addition, in a recent, direct comparison between N1 and N2 TANs, we found a significant number of pathways altered between the 2 subpopulations, including cytoskeletal organization, phagocytosis, and most important, immune response and chemokine activity [28] . In fact, one of the most prominent, significant differences we found between N1 and N2 TANs was their cytokine and chemokine signature, supporting the notion that tumor neutrophils have an important role in the recruitment of immunocytes and in the balance between states of activation and suppression of the immune system in cancer. N1 TANs expressed higher levels of the proinflammatory cytokines IL-12 and Tnf-a, together with various T cell-and macrophageattracting chemokines (Cxcl10, Ccl7, Ccl2 and Ccl3). Ccl17 and Cxcl14 were the 2 most strongly down-regulated chemokines in N1 TANs compared with N2 TAN. Indeed, we have demonstrated the active secretion of CCL17 by N2 TANs, which was followed by active recruitment of T regs to the tumor microenvironment. Depletion of tumor neutrophils strongly reduced the chemoattraction of T regs to the tumor [43] . In our transcriptomic analysis, we also noted that N2 TANs can express Tgf-b1. IL-6 and IL-23, a combination of cytokines which has been suggested to promote Th17 priming. CXCL14, in contrast, possesses chemoattractive activity for activated macrophages, immature DCs, and NK cells. We are currently studying the chemokine secretion profile and consequent differential recruitment of immunocytes by the various neutrophil subpopulations.
Altogether, these data reinforce the concept that TANs are an active source for cytokines and chemokines inside tumors and may, therefore, be an active and important orchestrator of innate and adaptive immunity in the tumor microenvironment.
BIDIRECTIONAL INTERACTIONS AMONG TAN AND OTHER IMMUNE CELLS TOWARD AN IMMUNOSUPPRESSIVE ENVIRONMENT
In addition to neutrophils, the functions of a variety of immune cell types, including macrophages, DCs, T cells, and NK cells, are modulated after their recruitment to the tumor microenvironment. TAMs, for example, which display an inflammatory (M1, "classically activated") cytotoxic phenotype at early stages of the tumor [44] , polarize toward an "alternatively activated" (M2) phenotype as the tumor progresses [45] , exhibiting a protumor, proangiogenic, and immunoinhibitory phenotype [46] . Similar polarization has been demonstrated for tumor-infiltrating DCs [47] [48] [49] and NK cells [50] , which were shown to be suppressed in the tumor microenvironment. CTL suppression and exclusion have also been shown to allow tumor cells to evade immune responses [51] . Many mechanisms for CTL exclusion have been described, including the blocking of CTL recruitment [52, 53] , inhibition of T cell functions through the PDL1 checkpoint [54, 55] , and a change in extracellular matrix composition, blocking T cell infiltration [56, 57] . In addition, a variety of T-cell subsets displaying protumor activity (Th2 response), including CD4 + T regs , are attracted to the tumor [58] and accumulate within it [59] . In addition to the many mechanisms described above, the existence of multiple crosstalks among tumor-associated neutrophils and other infiltrating immune cell types has been shown to promote evasion from immunosurveillance (Fig. 1) .
Increasingly, studies in recent years, mostly in murine models of cancer, have explored the interactions of TANs and T cells. Neutrophils and T cells can modulate the function of each other at many levels, either in a contact-dependent manner or through cytokine secretion. In the context of cancer, tumor-infiltrating Th17 cells and IL-17 were demonstrated to promote tumor growth and neutrophil mobilization [60] , to induce the expression of CXCL8/IL-8 in epithelial cells, which, in turn, recruit neutrophils to the tumor microenvironment and cause expression of G-CSF, leading to immature myeloid cell mobilization and recruitment. IL-17-producing gd T cells promote neutrophil expansion and polarization in a G-CSF-dependent way in tumor-bearing mice [61] . Neutralization of IL-17 or G-CSF or depletion of the gd T cells prevented the T-cell-suppressive phenotype of neutrophils. Recently, human gd T cells were shown to contribute to the recruitment, survival, and proliferation of tumor-infiltrated G-MDSCs in colorectal cancer through the release of IL-17A, CXCL8, GM-CSF, and TNF-a [62] .
In addition, we have reported that, depending on their polarization and protumor (N1) or antitumor (N2) profile, TANs can differentially affect T cell subsets [26, 43] . T regs displaying protumor properties are preferentially recruited by N2 TANs. By secreting CCL17, we showed that N2 TANs recruit CD4 + T regs to the tumor site, thus, inducing immunologic self-tolerance and impaired immune response to tumor cells [43] . Other recent studies have explored the interactions of TANs with CD8 + CTLs, which are capable of having significant antitumor activity. By producing T cell-attracting chemokines (e.g., CCL3, CXCL9, and CXCL10) and proinflammatory cytokines (e.g., IL-12, TNF a, and GM-CSF), N1 TANs can promote CD8 + T cell recruitment and activation [26, 63] . In accordance with this chemotactic profile, we have shown that CD8 + cell depletion in mice impairs neutrophil mobilization to the tumor and blocks the anti-TGF-b effect on tumor size [26] . These results indicate that the presence of CD8 + T cells is critical for the antitumor effect of the TGF-b blockade and N1 TANs.
As we presented at the regulatory myeloid suppressor cells conference organized by the Wistar Institute (Philadelphia PA, USA), in June 2016, we also found and will soon report that TANs can directly affect CD8 + T cell survival, activation, and proliferation (unpublished data).
In addition to their effect on T cell subsets, and as shown in detail in Fig. 1 , TANs mediate immune editing and modulation of other tumor-infiltrating immune cells [22] . TANs were reported to activate DCs via cell-cell contact and through secretion of TNF-a, promoting tumor regression in an IL-12-dependent manner [64] . Recently, TANs were also shown to facilitate metastasis by inhibiting NK activation and their IFN-g secretion, thereby preventing NK cell-mediated clearance of circulating cancer cells after extravasation [65] . Furthermore, neutrophils activate and recruit macrophages at sites of inflammation through the secretion of IL8, TNF-a, and MPO [66] . High MPO expression by infiltrating TANs in some cancers and its possible involvement in early stages of cancer [67, 68] have raised the question of a possible TAN-TAM interaction, although direct evidence is still lacking [34] .
NEUTROPHILS IN HUMAN CANCER
Limited data exist regarding human neutrophils in cancer and human TANs, in particular. Histologic studies performed on a variety of tumor types have shown that high levels of intratumoral neutrophils are associated with poor outcomes for patients with several cancer types, such as renal cell carcinoma, melanoma, colorectal cancer, and head and neck cancer [13] . The extent of neutrophil infiltration was found to correlate with tumor grade in human gliomas [69] and to be related to aggressive types of pancreatic tumors [70] . In contrast, a high neutrophil count in gastric tumors was reported to be associated with a favorable prognosis [71] . Many patients with advanced cancer show high levels of blood neutrophilia [72] . The mechanisms by which neutrophilia is induced in patients with cancer are uncertain, although several cytokines secreted by solid tumors have been suggested to contribute to that phenomenon and to promote suppressive properties in circulating neutrophils [73] .
Our understanding of the function of neutrophils in human cancer also remains vague, but recent studies support the notion that TANs in human cancer are capable of modulating T cell functions. TANs isolated from patients with non-small cell lung cancer were shown to respond to IL-8 (secreted by tumor cells) by releasing Arg-1 to the environment, resulting in direct, immunosuppressive effects on cytotoxic CD8 + T cells [74] .
Recently, Eruslanov et al. [33] demonstrated that, at early stages of human lung cancer, TANs secrete a large panel of cytokines and chemokines, with a preponderance of proinflammatory cytokines, such as IFN-g, IL-12, and TNF-a, whereas there was little expression of anti-inflammatory cytokines (IL-4, IL-10). These TANs from early cancer stages were also shown to acquire an activated phenotype compared with circulating peripheral blood neutrophils, with high phagocytic activity, high ROS production, and an altered cytokine profile [33] . These phenotypic changes correlated with the TAN ability to stimulate both CD4 and CD8 T cell proliferation and activation. TAN expression of costimulatory molecules OX40L, 4-1BBL, and CD54 is critical for these effects. In a study of human lung cancer, a new subset of TANs, showing both neutrophil characteristics and APC properties, was recently identified [75] . These "hybrid neutrophils" were shown to trigger antitumor T cell responses in a GM-CSF-and IFN-g-dependent manner.
Recent studies have reported that circulating neutrophils isolated from tumor-bearing mice and from individuals with cancer [76, 77] show increased predisposition to form NETs-web-like fibers formed by decompacted chromatin and proteases. First described as a novel defense mechanism during severe bacterial infections [78] , NETs are formed when activated neutrophils externalize their chromatin and granular content and form a meshwork of DNA strands that function as a trap for microbes. Two forms of NETosis have been described: "suicidal NETosis" is a form of neutrophil death, distinct from apoptosis or necrosis, which classically occurs after stimulation with PMA; and "vital NETosis," which has been described as an alternative pathway that does not involve cell lysis. This second pathway can be activated by LPS and pathogens, is a quicker process, and allows the neutrophils to retain their cellular functions after the release of NETs [79] . The differential contribution of the various cancer-related neutrophil subtypes in tumor-induced NET formation is, as yet, unknown. NETosis requires the production of ROS [80] and MPO [81] and the translocation of neutrophil elastase from azurophilic granules to the nucleus [82] . Although a link between the presence of NETs and neutrophil recruitment to the tumor has been suggested, the existence and function of NETosis in tumor-associated neutrophils is still not clear [77] . The release of NETs in adaptive and innate immunity acts as a direct modulator of T cells and DCs. NETs released by human neutrophils were shown to directly prime T cells in a contact-and TCR signaling-dependent mechanism, increasing T cell responses to Ags [83] . NETs not only trigger plasmacytoid DC activation in a TLR9-dependent way [84] but also can, conversely, impair LPS-induced maturation of monocyte-derived DCs [85] . The few studies conducted so far, looking at the consequences of NETosis in individuals with cancer, suggest that tumor-induced NETosis may contribute directly to malignant progression and associated complications [86] , such as an increased risk for metastasis or impaired vascular function [87] .
CANCER-RELATED NEUTROPHILS AS POTENTIAL PLAYERS IN CURRENT AND FUTURE IMMUNOTHERAPIES FOR CANCER
The accumulating data on TAN function in cancer and the discovery that TANs can be manipulated toward more-cytotoxic phenotypes have made tumor-related neutrophils (circulating or intratumoral) a new possible target for cancer immunotherapy. It is still not clear whether cancer-related neutrophils could be polarized therapeutically in patients with cancer or whether an N2-to-N1 shift could be applied to human patients, but interference with their protumor activity is hypothesized to result in tumor regression or delayed tumor progression. A general reduction in circulating neutrophils has not been seen as a preferred option because of the risk of complications, primarily an increased risk of infection.
Based on the studies showing that TGF-b is highly expressed in many tumors and modulates multiple processes during tumor development [88] , several trials have tested the option of manipulating TGF-b in patients with cancer [89] . Early developments targeting TGF-b encountered difficulties because of the involvement of TGF-b in multiple physiologic pathways and were stopped. New molecules directed toward either TGF-b or its receptors are currently being tested in clinical trials [89] . TGF-b has long been known to be a potent chemoattractant for neutrophils [90] , but its exact effect on circulating or intratumoral neutrophils in human cancer is still unknown. Further studies are needed to understand how manipulating TGF-b in patients with cancer might affect the different subsets of neutrophils.
Other therapies directed toward immune checkpoints, originally aiming at modulating T cells, were, in some cases, shown to affect myeloid cells, including neutrophils. Blockade of CTLA4, for example, resulted in reduced numbers of G-MDSCs in patients with melanoma [91] . Following indications of PDL1 expression on circulating neutrophils in the context of systemic inflammation [92] and tuberculosis infection [93] , increased expression of PDL1 on circulating neutrophils [94] was also demonstrated in the context of cancer. These findings raised the question of an effect of anti-PD-1 treatment on neutrophils, which is still being studied.
CONCLUSIONS
Immune cells represent a major part of the nonmalignant, tumor-infiltrating cells and have a critical role in promoting a unique, immune-suppressive, tumor-promoting microenvironment. Numerous signals mediate a variety of crosstalks between tumor cells and immune cells, which help promote tumor growth and progression. TANs, an important constituent of many tumors and metastatic lesions, express and secrete a variety of cytokines, chemokines, and other mediator molecules. These can affect the proliferation, activation, survival, and recruitment of a variety of immune cell types in the tumor microenvironment, including neutrophils, macrophages, MDSCs, T cells, DCs, and others, suggesting that neutrophils may eventually be determined to be important in driving the immunosuppressive switch [5, 21, 22] . However, neutrophil polarization and recruitment are also modified by multiple factors secreted from tumor cells and other tumor-infiltrating immune cells. One of the major questions regarding neutrophil polarization in the context of cancer is whether their "alternative activation state" is a result of a functional plasticity or a consequence of the infiltration of distinct populations at different time points during tumor progression. There is evidence that different neutrophil subsets present some N1 vs. N2 properties already in the circulation. These findings support the idea of a predisposition of neutrophils before their infiltration to the tumor. However, we still do not fully understand the signals establishing neutrophil polarization in different tumor niches. For example, it is possible that, in contrast to their immune-suppressive characteristics in the primary tumor microenvironment, neutrophils in the premetastatic organs may show antitumorigenic properties [19, 20] . More studies are needed to characterize and understand the various forces orchestrating the recruitment and polarization of the different subpopulations of neutrophils in the context of cancer and their multiple effects on tumor cells and immune cells in the tumor microenvironment. 
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